The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

Biosimilars are similar and relatively affordable ... 1:51 PM UTC · Updated ago Sustainable Finance & Reportingcategory Pfizer beats profit estimates on cost cuts, COVID vaccine sales 1:27 ...